Compare WFC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFC | NVO |
|---|---|---|
| Founded | 1852 | 1923 |
| Country | United States | Denmark |
| Employees | 200999 | 69500 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.7B | 218.9B |
| IPO Year | N/A | N/A |
| Metric | WFC | NVO |
|---|---|---|
| Price | $87.69 | $51.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 11 |
| Target Price | ★ $96.59 | $51.00 |
| AVG Volume (30 Days) | ★ 10.3M | 9.1M |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | 2.21% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.08 | N/A |
| Revenue Next Year | $4.76 | $3.70 |
| P/E Ratio | $14.15 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.78 | $35.12 |
| 52 Week High | $97.76 | $71.80 |
| Indicator | WFC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 70.43 |
| Support Level | $80.15 | $50.55 |
| Resistance Level | $95.47 | $53.63 |
| Average True Range (ATR) | 2.00 | 1.04 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 85.42 | 93.72 |
Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.